Advancement and Validation of Prostate Diffusion and Spectroscopic MRI

前列腺扩散和能谱 MRI 的进展和验证

• 批准号: 8299893
• 负责人: Stephan E Maier
• 金额: $ 40.87万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-04-01 至 2017-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8299893
• 关键词: Address; Aftercare; Agreement; Anatomy; Biopsy; Cancer Patient; Cell membrane; Choline; Citrates; Clinical; Collection; Complement; Core Biopsy; Creatine; Data; Data Set; Detection; Development; Diagnostic; Diffusion; Diffusion Magnetic Resonance Imaging; Diffusion weighted imaging; Disease; Exhibits; Gland; Gleason Grade for Prostate Cancer; Histology; Image; Individual; Lesion; Lipids; Local Therapy; Location; MRI Scans; Magnetic Resonance; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Malignant Neoplasms; Malignant neoplasm of prostate; Maps; Metabolic Marker; Methods; Microscopy; Monitor; Morphologic artifacts; Motion; Nature; Normal tissue morphology; PSA level; Patient Monitoring; Patients; Pelvis; Phase; Physiologic pulse; Play; Predisposition; Procedures; Prostate; Protocols documentation; Radical Prostatectomy; Resolution; Role; Scanning; Services; Shapes; Signal Transduction; Staging; System; Techniques; Testing; Time; Tissues; Transrectal Ultrasound; Tumor Tissue; Validation; Weight; abstracting; base; cancer site; follow-up; image registration; improved; novel; novel strategies; reconstruction; spectroscopic imaging; treatment effect; tumor; tumor growth; water diffusion

Project Summary/Abstract More reliable and accurate diagnostic estimation of tumor locations, volumes, and malignancy grade with MR would provide an invaluable service towards staging prostate cancer, particularly in cases with negative transrectal ultrasound (TRUS) biopsy. MR, due to the non-invasive nature, is a promising method for repeated exams in patients under active surveillance (AS) and for monitoring treatment effects. More detailed localization is also valuable for emerging targeted local therapies. The current collection of MR methods, which includes T2-weighted MRI, dynamic contrast-enhanced (DCE) MRI, diffusion-weighted MRI (DWI) and 3D-MR spectroscopic imaging (MRSI) appears to be very useful for staging of prostate cancer, particularly if used in combination. However, the potentially most sensitive and specific of these methods, namely DWI and MRSI, exhibit several deficiencies, which will be addressed by the technical developments contemplated for this project. Moreover, a novel contrast based on the separation of the fast and slow water diffusion components present in tissues, will be explored for improved detection of prostate cancer. The specific aims are as follows: 1) To advance whole-gland MRSI by reducing scan duration to a clinically acceptable time, while improving spatial resolution and eliminating the problem of lipid contamination of spectra due to truncation artifacts. 2) To advance spatial resolution and geometric fidelity of prostate DWI with reduced field-of-view and segmented multi-shot imaging. 3) To perform MRI scans in prostate cancer patients with standard sequences and new MRSI and diffusion imaging sequences. Moreover, to attain a separation of diffusion components, which have the potential to be more sensitive and specific to tumor growth related tissue aberrations at the cellular level, it is planned to employ biexponential analysis of DWI data collected over a wider range of diffusion encoding strength (b-factor). Quantitative parameter maps will be generated from MRSI, DWI, and DCE MRI data. 4) To obtain MRI-guided biopsy data or whole-gland step section histology during clinically indicated follow-up procedures in order to validate that the improved techniques and the novel contrast permit superior detection of prostate cancer. Pre-procedural parameter maps will be co-registered to the biopsy or histology coordinate system. Gleason scores of individual biopsy cores and tumor outlines on microscopy images will be compared with findings on parameter maps. The utility of each parameter and combined parameters to differentiate tumor from normal tissue will be analyzed statistically.

项目摘要/摘要 MR对肿瘤位置，体积和恶性等级的更可靠，准确的诊断估计将为分期前列腺癌提供宝贵的服务，尤其是在经直肠超声（TRUS）活检阴性的情况下。 MR由于非侵入性，是在主动监测（AS）和监测治疗效果下重复检查的一种有前途的检查方法。更详细的本地化对于新兴的目标局部疗法也很有价值。 当前的MR方法集合包括T2加权MRI，动态对比增强（DCE）MRI，扩散加权MRI（DWI）和3D-MR光谱成像（MRSI）似乎对于分布前列腺癌（尤其是组合使用）似乎非常有用。但是，这些方法（即DWI和MRSI）中可能最敏感和具体的，表现出几种缺陷，这将由该项目的技术发展解决。此外，将探索基于组织中存在的快速和慢速扩散成分的分离的新型对比，以改善对前列腺癌的检测。具体目的如下：1）通过将扫描持续时间减少到临床上可接受的时间，同时改善空间分辨率并消除由于截短伪影引起的光谱污染问题，以推动全gland MRSI。 2）以减少视野和分段的多弹射成像来推进前列腺DWI的空间分辨率和几何保真度。 3）在具有标准序列以及新的MRSI和扩散成像序列的前列腺癌患者中进行MRI扫描。此外，要获得扩散成分的分离，这些扩散成分有可能在细胞水平上对肿瘤生长相关的组织像差更敏感，并且计划对在更广泛的扩散强度（B因子）中收集的DWI数据进行Biexpential分析。定量参数图将从MRSI，DWI和DCE MRI数据产生。 4）在临床指定的随访程序中获得MRI引导的活检数据或整个Gland步骤部分组织学，以验证改进的技术和新颖的对比度允许对前列腺癌的出色检测。 术前参数图将共同注册到活检或组织学坐标系统。将比较显微镜图像上单个活检核心和肿瘤轮廓的Gleason评分与参数图的发现。每个参数和组合参数的实用性将在统计上分析肿瘤与正常组织的区分。